Renal Denervation Devices Market: Key Companies & Innovations

Renal Denervation Devices Market Companies

• Ablative Solutions, Inc.
• Abbott
• Avinger/related interventional companies
• Boston Scientific Corporation
• Kona Medical, Inc
• Mercator MedSystems, Inc
• Medtronic plc
• Neuravi/Renal-focused interventional firms
• PulseCath Technologies/investigational device firms
• ReCor Medical, Inc.
• Renal Dynamics Limited
• SoniVie/CardioSonic(historical ultrasound/early programs)
• Symple Surgical, Inc.
• Terumo Corporation
• Vascular/specialty device firms offering RDN-capable platforms

Get Sample Report

Ablative Solutions, Inc.

• Company Name and Headquarters: Ablative Solutions, Inc. (Kalamazoo, Michigan, USA)

• Product Offerings related to Renal Denervation Devices: Ablative Solutions is developing the Peregrine System Kit, which uses an ethanol-based chemical ablation approach delivered via a catheter to denervate the renal arteries.

• Market Share and Estimated Revenue from Renal Denervation Devices Segment: As a company with a device still in clinical trials and not yet widely commercialized, its current market share and direct revenue from RDN devices are negligible. Revenue will depend on regulatory approval and market adoption.

• Recent Developments, Partnerships, or Innovations:

  • Ongoing clinical trials for the Peregrine System (e.g., TARGET BP I, TARGET BP OFF-MED).

  • Focus on demonstrating sustained blood pressure reduction and safety.

  • Exploring the unique mechanism of action of ethanol ablation compared to radiofrequency.

• Competitive Positioning and Strategic Focus: Differentiated by its ethanol-based chemical denervation approach, which targets the adventitial nerve fibers more broadly than intimal RF ablation. This positions them as an alternative for patients who might not respond to or be suitable for RF-based systems.

• Key Customers or Industries Served: Currently, primarily clinical researchers and institutions participating in their trials. Post-commercialization, interventional cardiologists, nephrologists, and hypertension specialists.

Abbott

• Company Name and Headquarters: Abbott Laboratories (Abbott Park, Illinois, USA)

• Product Offerings related to Renal Denervation Devices: While Abbott is a major player in cardiovascular devices, they have not publicly disclosed a dedicated, actively developed RDN system in their current portfolio. Their focus in hypertension management often lies in diagnostic tools, drug-eluting stents (which could be relevant for renal artery stenosis but not RDN), and structural heart devices. It’s possible they have investigational programs or partnerships not widely publicized.

• Market Share and Estimated Revenue from Renal Denervation Devices Segment: Currently negligible or non-existent in the dedicated RDN market.

• Recent Developments, Partnerships, or Innovations: Abbott continuously innovates in cardiovascular care, but specific RDN innovations are not a public part of their strategy at present. They are strong in areas like continuous glucose monitoring, structural heart, and rhythm management.

• Competitive Positioning and Strategic Focus: As a diversified healthcare giant, Abbott’s strategic focus is broad. If they were to enter RDN, they would leverage their extensive global sales channels, R&D capabilities, and existing relationships with cardiologists.

• Key Customers or Industries Served: Hospitals, clinics, physicians (cardiologists, endocrinologists, etc.), and patients across a wide range of medical specialties.

Avinger/related interventional companies

• Company Name and Headquarters: Avinger, Inc. (Redwood City, California, USA)

• Product Offerings related to Renal Denervation Devices: Avinger is primarily known for its image-guided, catheter-based systems for treating peripheral artery disease (PAD), using optical coherence tomography (OCT) guidance (e.g., Pantheris, Ocelot). While their platform involves advanced interventional catheters, they have not directly developed or marketed a dedicated RDN device. However, “related interventional companies” could broadly refer to firms with catheter-based platforms that could potentially be adapted for RDN.

• Market Share and Estimated Revenue from Renal Denervation Devices Segment: Negligible.

• Recent Developments, Partnerships, or Innovations: Avinger focuses on advancing its image-guided atherectomy and revascularization technologies for PAD. Any involvement in RDN would likely be through a future strategic pivot, partnership, or adaptation of their existing catheter technology.

• Competitive Positioning and Strategic Focus: Avinger differentiates itself with its Lumivascular technology, providing real-time intravascular imaging during interventions. This precision could be beneficial in RDN, but it’s not their current focus.

• Key Customers or Industries Served: Vascular surgeons, interventional radiologists, and interventional cardiologists treating peripheral artery disease.

Boston Scientific Corporation

• Company Name and Headquarters: Boston Scientific Corporation (Marlborough, Massachusetts, USA)

• Product Offerings related to Renal Denervation Devices: Boston Scientific previously had a renal denervation program, including devices like the Vessix Renal Denervation System, which used radiofrequency ablation. However, they divested this technology to Medtronic in 2013, focusing their efforts elsewhere. They currently do not have a dedicated RDN device on the market or in active development.

• Market Share and Estimated Revenue from Renal Denervation Devices Segment: Currently negligible.

• Recent Developments, Partnerships, or Innovations: Boston Scientific is a leader in a broad range of medical devices, including interventional cardiology (stents, structural heart), electrophysiology, and peripheral interventions. Their focus in hypertension is more on related areas like heart failure management devices.

• Competitive Positioning and Strategic Focus: A major global medical technology company with strong market positions in many cardiovascular and peripheral device segments. If they re-entered RDN, they would leverage their vast resources and existing physician relationships.

• Key Customers or Industries Served: Hospitals, interventional cardiologists, electrophysiologists, vascular surgeons, urologists, and other specialists globally.

Kona Medical, Inc.

• Company Name and Headquarters: Kona Medical, Inc. (Bellevue, Washington, USA)

• Product Offerings related to Renal Denervation Devices: Kona Medical developed the Surround Sound® System, a non-invasive RDN technology that uses focused ultrasound delivered from outside the body to ablate renal nerves. This approach aims to reduce the risks associated with invasive catheter-based procedures.

• Market Share and Estimated Revenue from Renal Denervation Devices Segment: As a company focused on novel, non-invasive technology, its market share and revenue are nascent, dependent on regulatory approvals and widespread adoption.

• Recent Developments, Partnerships, or Innovations:

  • Conducted clinical trials (e.g., REDUCED trial) to assess the safety and efficacy of their non-invasive focused ultrasound system.

  • Emphasizing the potential for a safer, outpatient RDN procedure.

• Competitive Positioning and Strategic Focus: Highly differentiated by its non-invasive approach. This positions them as a potential game-changer if long-term efficacy and safety are robustly demonstrated, appealing to patients and physicians seeking less invasive options.

• Key Customers or Industries Served: Currently clinical investigators. Post-commercialization, potentially cardiologists, nephrologists, and hypertension specialists, likely in an outpatient or clinic setting due to its non-invasive nature.

Mercator MedSystems, Inc.

• Company Name and Headquarters: Mercator MedSystems, Inc. (San Carlos, California, USA)

• Product Offerings related to Renal Denervation Devices: Mercator MedSystems developed the Bullfrog® Micro-Infusion Device, which is designed for local drug delivery. While not a direct RDN device itself, the Bullfrog system can be used to deliver therapeutic agents (like alcohol) to the perivascular space surrounding the renal arteries. This positions it as an enabling technology for chemical denervation, similar in concept to Ablative Solutions’ approach, but focusing on the delivery system.

• Market Share and Estimated Revenue from Renal Denervation Devices Segment: Negligible direct share. Its impact would be through partnerships where its delivery system is utilized for RDN.

• Recent Developments, Partnerships, or Innovations:

  • Focus on local drug delivery for various vascular applications, including potential for RDN.

  • Innovations in targeted, controlled perivascular drug delivery.

• Competitive Positioning and Strategic Focus: Positioned as a platform technology provider for local therapeutic delivery. Its strategic focus is on partnering with companies developing specific agents for perivascular therapies, including RDN.

• Key Customers or Industries Served: Other medical device companies, researchers, and potentially interventionalists for various vascular applications beyond RDN.

Medtronic plc

• Company Name and Headquarters: Medtronic plc (Dublin, Ireland – operational headquarters in Minneapolis, Minnesota, USA)

• Product Offerings related to Renal Denervation Devices: Medtronic is arguably the market leader and most prominent player in RDN. Their flagship product is the Symplicity Spyral™ Renal Denervation System, which uses a multi-electrode radiofrequency (RF) ablation catheter. They also acquired the Vessix RDN system from Boston Scientific.

• Market Share and Estimated Revenue from Renal Denervation Devices Segment: Medtronic holds a dominant position in the RDN market, particularly with the Symplicity system receiving significant regulatory approvals and demonstrating strong clinical trial results (e.g., SPYRAL HTN-OFF MED, SPYRAL HTN-ON MED). Their revenue from RDN devices is significant and growing, though specific figures are usually not broken out from their broader cardiovascular portfolio.

• Recent Developments, Partnerships, or Innovations:

  • FDA approval in the US for the Symplicity Spyral system in November 2023, a major milestone.

  • CE Mark in Europe and approvals in numerous other countries.

  • Extensive clinical trial program demonstrating safety and efficacy across diverse patient populations.

  • Focus on ease of use and consistent lesion creation.

• Competitive Positioning and Strategic Focus: Medtronic’s long-standing commitment to RDN, extensive clinical evidence, regulatory approvals, and global commercial infrastructure give them a strong competitive edge. Their strategic focus is on establishing RDN as a mainstream treatment option for uncontrolled hypertension.

• Key Customers or Industries Served: Interventional cardiologists, nephrologists, hypertension specialists, hospitals, and medical centers worldwide.

Neuravi/Renal-focused interventional firms

• Company Name and Headquarters: Neuravi, Inc. (acquired by Johnson & Johnson in 2017) (Mountain View, California, USA)

• Product Offerings related to Renal Denervation Devices: Neuravi was primarily focused on neurovascular devices for ischemic stroke treatment (e.g., EmboTrap revascularization platform). They did not develop or market RDN devices. The inclusion here likely refers to the broader category of “renal-focused interventional firms” that might have emerged or existed with RDN programs. Many smaller biotech or medtech startups might fall into this category.

• Market Share and Estimated Revenue from Renal Denervation Devices Segment: Neuravi had no direct RDN market share or revenue. For other generic “renal-focused interventional firms,” this would vary greatly, but many are in early development or niche stages.

• Recent Developments, Partnerships, or Innovations: (For Neuravi) Acquisition by J&J solidified its neurovascular contributions. (For generic firms) Innovation often revolves around novel energy sources (e.g., ultrasound, cryoablation), different catheter designs, or non-invasive approaches.

• Competitive Positioning and Strategic Focus: (For Neuravi) Focused on acute ischemic stroke. (For generic firms) Often seeks to differentiate with unique mechanisms of action, improved safety profiles, or greater efficacy compared to established RF systems.

• Key Customers or Industries Served: (For Neuravi) Neurovascular specialists. (For generic firms) Clinical researchers and eventually interventional cardiologists/nephrologists.

PulseCath Technologies/investigational device firms

• Company Name and Headquarters: PulseCath B.V. (Amsterdam, Netherlands)

• Product Offerings related to Renal Denervation Devices: PulseCath specializes in percutaneous ventricular assist devices (pVADs) for temporary hemodynamic support during high-risk PCI and for cardiogenic shock (e.g., iVAC systems). They do not have dedicated RDN devices. The “investigational device firms” broad category suggests that some startups or research-focused companies are exploring RDN with novel approaches.

• Market Share and Estimated Revenue from Renal Denervation Devices Segment: Negligible.

• Recent Developments, Partnerships, or Innovations: PulseCath focuses on advancing its pVAD technology. Any RDN involvement would be highly speculative for this specific company. For broader investigational firms, innovations might include novel energy sources, targeted nerve disruption, or combining RDN with other therapies.

• Competitive Positioning and Strategic Focus: (For PulseCath) Focused on acute cardiac support. (For investigational firms) Often aiming to disrupt the market with new technologies that offer better outcomes or fewer side effects.

• Key Customers or Industries Served: (For PulseCath) Interventional cardiologists in cath labs. (For investigational firms) Researchers, and eventually interventionalists.

ReCor Medical, Inc.

• Company Name and Headquarters: ReCor Medical, Inc. (Palo Alto, California, USA – acquired by Otsuka Medical Devices Co., Ltd.)

• Product Offerings related to Renal Denervation Devices: ReCor Medical is a significant player in the RDN market with its Paradise™ Renal Denervation System, which utilizes focused ultrasound energy delivered circumferentially to ablate renal nerves.

• Market Share and Estimated Revenue from Renal Denervation Devices Segment: ReCor is a strong contender and challenger to Medtronic, particularly following positive clinical trial results (e.g., RADIANCE-HTN TRIO, RADIANCE-HTN SOLO) and regulatory approvals. Their market share is growing, and revenue is increasing, though specific RDN figures are not publicly isolated.

• Recent Developments, Partnerships, or Innovations:

  • FDA approval in the US for the Paradise system in November 2023, a major achievement.

  • CE Mark in Europe and approvals in other regions.

  • Clinical evidence supporting the efficacy and safety of their ultrasound-based approach.

  • Acquisition by Otsuka Medical Devices provides significant financial and commercial backing.

• Competitive Positioning and Strategic Focus: ReCor is positioned as a key competitor to Medtronic, offering an ultrasound-based alternative to RF ablation. Their strategic focus is on expanding market access and demonstrating the clinical utility of their system in a broader patient population.

• Key Customers or Industries Served: Interventional cardiologists, nephrologists, hypertension specialists, hospitals, and medical centers globally.

Renal Dynamics Limited

• Company Name and Headquarters: Renal Dynamics Limited (Headquarters information not readily available, often smaller or privately held companies may not publicly list detailed HQ)

• Product Offerings related to Renal Denervation Devices: Information on specific RDN product offerings for “Renal Dynamics Limited” is not widely available in major market reports or public databases, suggesting it may be a smaller, investigational-stage, or niche firm, or perhaps an older entity that is no longer active in RDN. It’s possible they had early-stage RDN concepts or patents.

• Market Share and Estimated Revenue from Renal Denervation Devices Segment: Likely negligible or non-existent in the current commercial market.

• Recent Developments, Partnerships, or Innovations: Without specific public information, it’s hard to detail recent activities. Any innovations would likely be in novel energy delivery or targeting mechanisms.

• Competitive Positioning and Strategic Focus: If active, would likely be focused on developing a differentiated RDN technology to address unmet needs.

• Key Customers or Industries Served: Likely research and development-focused, potentially seeking partnerships with larger firms.

SoniVie/CardioSonic(historical ultrasound/early programs)

• Company Name and Headquarters: SoniVie Ltd. (Misgav, Israel) / CardioSonic (historical reference to early ultrasound-based RDN programs, sometimes associated with specific research or early corporate entities)

• Product Offerings related to Renal Denervation Devices: SoniVie is developing the TIVUS® System (Therapeutic IntraVascular UltraSound) for renal denervation. This system uses therapeutic ultrasound delivered via a catheter to ablate renal nerves.

• Market Share and Estimated Revenue from Renal Denervation Devices Segment: As a company with a device in clinical development, its current market share and revenue from RDN devices are negligible, dependent on future commercialization.

• Recent Developments, Partnerships, or Innovations:

  • Ongoing clinical trials (e.g., the REDUCED HTN clinical study).

  • Focus on an ultrasound-based approach, similar to ReCor, but potentially with different delivery or energy profiles.

  • Emphasis on a non-occlusive, conformable device for diverse renal artery anatomies.

• Competitive Positioning and Strategic Focus: Positioned as an innovator in ultrasound-based RDN, seeking to demonstrate superior safety or efficacy, or a broader applicability due to its catheter design.

• Key Customers or Industries Served: Clinical researchers. Post-commercialization, interventional cardiologists, nephrologists, and hypertension specialists.

Symple Surgical, Inc.

• Company Name and Headquarters: Symple Surgical, Inc. (San Mateo, California, USA – acquired by Medtronic in 2012)

• Product Offerings related to Renal Denervation Devices: Symple Surgical was an early pioneer in renal denervation, developing a multi-electrode RF ablation catheter system. Their technology and intellectual property were acquired by Medtronic in 2012, forming a foundational part of Medtronic’s Symplicity RDN program.

• Market Share and Estimated Revenue from Renal Denervation Devices Segment: As a standalone entity, Symple Surgical no longer has direct market share or revenue. Its technology contributed significantly to Medtronic’s market leadership.

• Recent Developments, Partnerships, or Innovations: The key “development” was its acquisition by Medtronic, integrating its innovations into a larger platform.

• Competitive Positioning and Strategic Focus: Before acquisition, focused on developing an effective multi-electrode RF denervation system. Its strategic contribution was to accelerate Medtronic’s entry and dominance in the RDN space.

• Key Customers or Industries Served: N/A as a standalone entity; its technology now serves Medtronic’s customer base.

Terumo Corporation

• Company Name and Headquarters: Terumo Corporation (Tokyo, Japan)

• Product Offerings related to Renal Denervation Devices: Terumo is a global medical device manufacturer with a strong presence in interventional cardiology (guide wires, catheters, stents, access devices). While they provide many components used in interventional procedures, they have not publicly introduced a dedicated RDN system in their portfolio. It’s plausible they could develop one or partner in the future, given their expertise in catheter-based technologies.

• Market Share and Estimated Revenue from Renal Denervation Devices Segment: Currently negligible.

• Recent Developments, Partnerships, or Innovations: Terumo continuously innovates in areas like percutaneous coronary intervention (PCI), peripheral interventions, and drug-coated balloons. Their expertise in vascular access and delivery systems positions them well if they choose to enter the RDN space.

• Competitive Positioning and Strategic Focus: A diversified medical technology company with a strong reputation for quality and precision in vascular devices. Their strategic focus is broad across cardiovascular, peripheral, and other medical fields.

• Key Customers or Industries Served: Interventional cardiologists, radiologists, vascular surgeons, hospitals, and medical clinics globally.

Vascular/specialty device firms offering RDN-capable platforms

• Company Name and Headquarters: This is a broad category encompassing numerous smaller, innovative companies, often privately held, or larger firms with complementary technologies. Examples might include:

  • CathWorks (Israel) – focused on FFR analysis, but platform could be integrated.

  • Shockwave Medical (USA) – intravascular lithotripsy, not RDN, but a novel energy delivery platform.

  • Various startups developing novel ablation technologies (e.g., cryoablation, pulsed field ablation) that could be adapted for renal denervation.

• Product Offerings related to Renal Denervation Devices: These firms typically don’t have dedicated RDN devices but possess platforms (e.g., advanced catheters, energy delivery systems, imaging technologies) that could be adapted or partnered for RDN applications. This might involve different energy sources (cryo, pulsed field, laser) or more precise navigation.

• Market Share and Estimated Revenue from Renal Denervation Devices Segment: Individually, these firms would have negligible or no direct RDN market share. Their contribution would be enabling technology or future RDN solutions.

• Recent Developments, Partnerships, or Innovations: Continuous innovation in catheter design, energy delivery, and intravascular imaging. Many seek partnerships with larger players or aim for niche markets.

• Competitive Positioning and Strategic Focus: Often focused on disruptive technologies, seeking to carve out a specialized niche or provide an enabling platform for a broader range of therapeutic applications, including potential RDN.

• Key Customers or Industries Served: Other medical device manufacturers, interventional specialists (cardiologists, radiologists, vascular surgeons), and researchers exploring new therapeutic frontiers.

Contact Us